CILO-203

CILO-203 is a preclinical-stage therapeutic small extracellular vesicle (sEV), or exosome, being developed by Ciloa for the treatment of oncology indications. The asset is generated using Ciloa's proprietary platform, which enables the customized expression of specific proteins on the surface or within the lumen of exosomes in vivo. This technology leverages the natural signaling and delivery capabilities of exosomes to target malignant cells or modulate the tumor microenvironment. While the specific molecular target of CILO-203 is currently undisclosed, it is part of a pipeline of therapeutic sEVs that includes candidates targeting immune checkpoints and other validated oncology pathways. The use of sEVs as a modality offers potential advantages in terms of biocompatibility, low immunogenicity, and the ability to deliver complex protein cargoes to specific tissues.